NCT00057512View on ClinicalTrials.gov

Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Head and Neck Neoplasms
Interventions
DRUG

M4N

Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.

Trial Locations (1)

29475

MUSC, Charleston

Sponsors

Collaborators (1)

Duke University
All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

Medical University of South Carolina

OTHER

lead

Erimos Pharmaceuticals

INDUSTRY

NCT00057512 - Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck | Biotech Hunter | Biotech Hunter